Expert Pitch
Binghamton University, State University of New York

State, municipal leaders can issue “right” COVID-19 policies even when national leaders put forth “wrong” policies

Democratic institutions, in particular federalism, can impact the speed and degree of policy responses protecting citizens during the COVID-19 pandemic, even when national leaders share public rhetoric that is non-conducive to speedy policy response, says an international group of researchers led by Olga Shvetsova, professor of political science and economics at Binghamton University, State University of New York. 

“The ongoing COVID-19 pandemic represents an existential threat to societies around the world. There has been considerable variation in both rhetoric and policy responses among the many national governments,” says the researchers. “Comparing the policies of the United States and United Kingdom with the backdrop of their national leaders’ public stances, having multiple decision points due to the redundancy inherent in federalism increases the chances that a citizen will receive the “correct” policy, even when policy-makers at some levels of government put forth “wrong” policy responses. 

The researchers pointed out that while President Donald Trump and Prime Minister Boris Johnson issued policy responses that downplayed the severity of COVID-19, state and municipal authorities stepped in with the “right” responses. 

“Systems with greater policy authority redundancies -- greater jurisdictional overlap in policy-making -- have a built in advantage,” says the researchers.

Binghamton University offers live or pre-taped interviews powered by a state-of-the-art ReadyCam television studio system, available at a moment’s notice. Our system can broadcast live HD audio and video to networks, news agencies, and affiliates interviewing Binghamton faculty, students, and staff. Video is transmitted by VideoLink and fees may apply.




Filters close

Showing results

110 of 2537
Newswise: John Theurer Cancer Center Part of a New Study
in COVID-19 Patients Suggesting Activity of a Novel Agent BTK Inhibitor Acalabrutinib used as Anti-Cancer Drug in B-cell Malignancies
Released: 13-Jul-2020 3:45 PM EDT
John Theurer Cancer Center Part of a New Study in COVID-19 Patients Suggesting Activity of a Novel Agent BTK Inhibitor Acalabrutinib used as Anti-Cancer Drug in B-cell Malignancies
Hackensack Meridian Health

The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation.

Newswise: National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Released: 13-Jul-2020 3:40 PM EDT
National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Department of Energy, Office of Science

To focus its efforts against the COVID-19 pandemic, DOE is bringing the national laboratories together into the National Virtual Biotechnology Laboratory.

Newswise: Key Insights from Swedish Casino that Remained Open During COVID-19
Released: 13-Jul-2020 3:40 PM EDT
Key Insights from Swedish Casino that Remained Open During COVID-19
University of Nevada, Las Vegas (UNLV)

As casinos in Las Vegas enter the second month of reopening since the COVID-19 pandemic took hold, UNLV gaming researchers say they can draw upon insights from industry collaborators in Sweden, a country that took a more open approach to the crisis compared to other governments.

Released: 13-Jul-2020 2:40 PM EDT
Engineered llama antibodies neutralize COVID-19 virus
Rosalind Franklin Institute

Antibodies derived from llamas have been shown to neutralise the SARS-CoV-2 virus in lab tests, UK researchers announced today.

Released: 13-Jul-2020 1:25 PM EDT
1 in 3 young adults may face severe COVID-19
University of California, San Francisco (UCSF)

As the number of young adults infected with the coronavirus surges throughout the nation, a new study by researchers at UCSF Benioff Children's Hospitals indicates that youth may not shield people from serious disease.

Released: 13-Jul-2020 12:25 PM EDT
Scientists discover key element of strong antibody response to COVID-19
Scripps Research Institute

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

Released: 13-Jul-2020 11:15 AM EDT
UTHealth joins study of blood pressure medication’s effect on improving COVID-19 outcomes
University of Texas Health Science Center at Houston

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.

Newswise: Drug that calms ‘cytokine storm’ associated with 45% lower risk of dying among COVID-19 patients on ventilators
Released: 13-Jul-2020 7:25 AM EDT
Drug that calms ‘cytokine storm’ associated with 45% lower risk of dying among COVID-19 patients on ventilators
Michigan Medicine - University of Michigan

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn’t receive the drug, according to a new observational study.

10-Jul-2020 9:00 AM EDT
Long-term strategies to control COVID-19 pandemic must treat health and economy as equally important, argue researchers
University of Cambridge

Strategies for the safe reopening of low and middle-income countries (LMICs) from months of strict social distancing in response to the ongoing COVID-19 pandemic must recognise that preserving people’s health is as important as reviving the economy, argue an international team of researchers.


Showing results

110 of 2537

close
3.79801